Since its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus is regarded as a global public health emergency. The existing therapeutic options for COVID-19 beyond the intensive supportive care are limited, with an undefined or modest efficacy reported so far. Drug repurposing represents an enthusiastic mechanism to use approved drugs outside the scope of their original indication and accelerate the discovery of new therapeutic options. With the emergence of COVID-19, drug repurposing has been largely applied for early clinical testing. In this review, we discuss some repurposed anticancer drugs for the treatment of COVID-19, which are under investigation in clinical trials or proposed for the clinical testing.

Repurposing anticancer drugs for the management of COVID-19 / K. El Bairi, D. Trapani, A. Petrillo, C. Le Page, H. Zbakh, B. Daniele, R. Belbaraka, G. Curigliano, S. Afqir. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 141(2020), pp. 40-61. [10.1016/j.ejca.2020.09.014]

Repurposing anticancer drugs for the management of COVID-19

D. Trapani;G. Curigliano
Conceptualization
;
2020

Abstract

Since its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus is regarded as a global public health emergency. The existing therapeutic options for COVID-19 beyond the intensive supportive care are limited, with an undefined or modest efficacy reported so far. Drug repurposing represents an enthusiastic mechanism to use approved drugs outside the scope of their original indication and accelerate the discovery of new therapeutic options. With the emergence of COVID-19, drug repurposing has been largely applied for early clinical testing. In this review, we discuss some repurposed anticancer drugs for the treatment of COVID-19, which are under investigation in clinical trials or proposed for the clinical testing.
Anticancer drugs; COVID-19; Repurposing; SARS-CoV-2; Antineoplastic Agents; Antiviral Agents; COVID-19; Humans; Pandemics; SARS-CoV-2; Drug Repositioning
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
El Bairi and Curigliano EJC 2020.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.25 MB
Formato Adobe PDF
1.25 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/824876
Citazioni
  • ???jsp.display-item.citation.pmc??? 23
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 37
social impact